Clozel’s Acte­lion R&D spin­out gets a name; GSK’s new CEO won’t make as much as her pre­de­ces­sor

→ Jean-Paul Clozel has a name for his biotech spin­out. Once J&J’s $30 bil­lion deal to ac­quire Acte­lion goes through, the R&D side of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.